What is NUVL's current stock price?

As of now, NUVL is trading at $102.23, with a daily change of -5.34%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NUVL Stock Analysis & IQ Rating | Nuvalent

NUVL

Nuvalent

$102.23

-$5.77 | -5.34%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

alert Latest Updates

BullPower Yesterday at 01:23

jumps 12.39% on volume of 1.95M shares, nearly four times its 30-day average of 503,016, following positive topline data from the ALKOVE-1 clinical trial of Neladalkib in ALK TKI pre-treated advanced ALK-positive NSCLC p...

NUVL Stock IQ

Login to see Nuvalent (NUVL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NUVL Target Price

Login to display

Strengths

NUVL Rewards

Upgraded on attractively valued

Chart

$97.18 (+5.20%)

$74.05 (+38.06%)

$79.68 (+28.30%)

$94.27 (+8.44%)

1year

6month

3month

1month

NUVL Risk Level

NUVL has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Moderate

LOW

HIGH

NUVL Analysts Opinion

NUVL overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

NUVL Analysts Opinion

NUVL Analysts opinion is negative but has improved from the past 3 months

NUVL Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

NUVL Street Sentiment

NUVL Street Sentiment is extremely bullish and have negative views on the near-term outlook

NUVL Performance Sentiment

Sentiments overview associated with NUVL events and the stock performance.

100%

0%

Positive

Negative

15 out of 15
events present

0 out of 15
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$96.74

Resistance
Price

$86.10

Current Price Range

$98.17

Show methods +

NUVL Latest Analysis +

HC Wainwright & Co. Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 17 2025 HC Wainwright &. Co. maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.48% Upside

Today

$102.23 | -5.34%

Rating

Stifel Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 17 2025 Stifel maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.48% Upside

Today

$102.23 | -5.34%

Rating

Nuvalent Shares Jump 14% After Positive Pivotal ALKOVE-1 Trial Results In ALK-Positive NSCLC . (RTTNews) - Nuvalent Inc. (NUVL) surged 14.24% to $110.24 up $13.74 following an announcement of strong topline data from its pivotal ALKOVE-1 trial evaluating neladalkib (NVL-655) in TKI-pretreated patients with ALK-positive non-small cell lung cancer (NSCLC).

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Momentum

Nuvalent announces public offering of common stock.

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer. NUVL) on Monday reported topline results from its .The study evaluated neladalkib in tyrosine kinase inhibitor (TKI)-pretreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The company said the recommended Phase 2 dose was set at 150 mg once daily selected during the Phase 1 dose-escalation stage.The primary analysis included 253 TKI-pretreated patients who had undergone a median of three

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer. Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental treatment.The post Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer appeared first on Investor'.s Business Daily.

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC. In 253 ALK TKI pre-treated patients ORR by BICR was 31% (95% CI: 26 37) with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks respectively In the subset of 63 TKI pre-treated patients who were lorlatinib-naïve ORR by BICR was 46% (95% CI:...

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Repare 30% Nuvalent 9% Lead After-Hours Biotech Gains . (RTTNews) - The after-hours session on Friday November 14 2025 brought notable moves across several biotech and therapeutics names as corporate updates financial results and strategic announcements drove sharp price reactions. From acquisition agreements to pivotal trial mi

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib. Company to host webcast and conference call on November 17 2025 at 8:00am ET CAMBRIDGE Mass. Nov. 14 2025 /PRNewswire/ -- Nuvalent Inc. (Nasdaq: NUVL) a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in...

Fri Nov 14, 2025

$96.74 | +1.84%

Activity

Canaccord Genuity Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation. Fintel reports that on November 12 2025 Canaccord Genuity initiated coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 25.46% Upside

Thu Nov 13, 2025

$94.68 | -2.42%

Rating

FAQ About NUVL Stock Insights

What is NUVL current stock price?

What are NUVL stock strengths?

What is NUVL Risk Level?

What is NUVL market cap and volume?

What is NUVL current Stock IQ?

Should I buy NUVL stock right now?

Is NUVL a Strong Buy right now?

What does a 'Strong Buy' rating mean for NUVL?

What does a 'Strong Sell' rating mean for NUVL?

What factors influence NUVL's Stock IQ?

Explore our NUVL Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NUVL Stock Strategies
Effective Risk Management

FIND US ON

Receive our NUVL Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NUVL

Nuvalent

Current Price

$102.23

-$5.77 | -5.34%

52W High

$112.53

MKT CAP

$7.52B

52W Low

$55.54

VOL

$348.14K

P/E Ratio

N/A

AVG VOL

$563.70K

RSI

59.18

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

NUVL Rewards

Upgraded on attractively valued

NUVL Stock IQ

Login to unlock Nuvalent (NUVL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$97.18 (+5.20%)

$74.05 (+38.06%)

$79.68 (+28.30%)

$94.27 (+8.44%)

1year

6month

3month

1month

NUVL Analysts Opinion

NUVL Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

NUVL Analysts Opinion

NUVL Analysts opinion is negative but has improved from the past 3 months

NUVL Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

NUVL Street Sentiment

NUVL Street Sentiment is extremely bullish and have negative views on the near-term outlook

NUVL Risk Level

NUVL has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Moderate

LOW

HIGH

NUVL Performance Sentiment

Sentiments overview associated with NUVL events and the stock performance.

100%

0%

Positive

Negative

15 out of 15
events present

0 out of 15
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$96.74

Resistance
Price

$86.10

Current Price Range

$98.17

Show methods +

NUVL Latest Analysis

BullPower Yesterday at 01:23

jumps 12.39% on volume of 1.95M shares, nearly four times its 30-day average of 503,016, following positive topline data from the ALKOVE-1 clinical trial of Neladalkib in ALK TKI pre-treated advanced ALK-positive NSCLC p...

HC Wainwright & Co. Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 17 2025 HC Wainwright &. Co. maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.48% Upside

Today

$102.23 | -5.34%

Rating

Stifel Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 17 2025 Stifel maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.48% Upside

Today

$102.23 | -5.34%

Rating

Nuvalent Shares Jump 14% After Positive Pivotal ALKOVE-1 Trial Results In ALK-Positive NSCLC . (RTTNews) - Nuvalent Inc. (NUVL) surged 14.24% to $110.24 up $13.74 following an announcement of strong topline data from its pivotal ALKOVE-1 trial evaluating neladalkib (NVL-655) in TKI-pretreated patients with ALK-positive non-small cell lung cancer (NSCLC).

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Momentum

Nuvalent announces public offering of common stock.

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer. NUVL) on Monday reported topline results from its .The study evaluated neladalkib in tyrosine kinase inhibitor (TKI)-pretreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The company said the recommended Phase 2 dose was set at 150 mg once daily selected during the Phase 1 dose-escalation stage.The primary analysis included 253 TKI-pretreated patients who had undergone a median of three

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer. Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental treatment.The post Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer appeared first on Investor'.s Business Daily.

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC. In 253 ALK TKI pre-treated patients ORR by BICR was 31% (95% CI: 26 37) with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks respectively In the subset of 63 TKI pre-treated patients who were lorlatinib-naïve ORR by BICR was 46% (95% CI:...

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Repare 30% Nuvalent 9% Lead After-Hours Biotech Gains . (RTTNews) - The after-hours session on Friday November 14 2025 brought notable moves across several biotech and therapeutics names as corporate updates financial results and strategic announcements drove sharp price reactions. From acquisition agreements to pivotal trial mi

Mon Nov 17, 2025

$108.00 | +11.92%

Activity

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib. Company to host webcast and conference call on November 17 2025 at 8:00am ET CAMBRIDGE Mass. Nov. 14 2025 /PRNewswire/ -- Nuvalent Inc. (Nasdaq: NUVL) a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in...

Fri Nov 14, 2025

$96.74 | +1.84%

Activity

Canaccord Genuity Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation. Fintel reports that on November 12 2025 Canaccord Genuity initiated coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 25.46% Upside

Thu Nov 13, 2025

$94.68 | -2.42%

Rating

Discover NUVL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NUVL. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NUVL Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NUVL Stock trends

NUVL Stock performance

NUVL Stock analysis

NUVL investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NUVL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NUVL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

NUVL Stock Analysis & IQ Rating | Nuvalent

NUVL Stock IQ

NUVL Target Price

NUVL Risk Level

NUVL Analysts Opinion

NUVL Street Sentiment

NUVL Performance Sentiment

Technical Price Levels

Explore our NUVL Stock insights

Receive our NUVL Daily Alerts

NUVL Stock IQ

NUVL Street Sentiment

NUVL Risk Level

Technical Price Levels

Discover NUVL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NUVL. We're here to help you make informed investment decisions today.

Receive our NUVL Daily Alerts

NUVL Runner Alarm